SKIN.L Regulatory News (SKIN)

Integumen plc

("Integumen" or "the Company")

Integumen signs Worldwide Patent Licence Agreement for remaining 50% of rights to Botox Booster IP

Integumen (LSE: SKIN), the personal health care company developing and commercialising technology and products for the human integumentary system, is pleased to announce it has signed a worldwide Patent Licence Agreement with Dr Gary Hack for his co-rights to various patents and know-how related to enhancing and extending the cosmetic benefits of botulinum toxin (commonly known as Botox) treatments as well as dermal fillers and rosacea known as the "Botox Booster IP".

Under the Agreement Integumen is due to pay an initial non-refundable consideration of $7,500 on or prior to October 31 2017 and will be liable to make additional milestone payments of up to $17,500 based on the issuance of patents in the US and Europe and the first sale or licensing of a product based on the Botox Booster IP. In addition, Dr Hack will receive royalty payments of 0.75% of the net sales of licensed products marketed directly by integumen or 5% of all monies received by Integumen from the sub-licensing of the IP, including any upfront payments, milestones and royalties.

The Botox Booster IP was jointly developed by Dr. Asculai, the Chief Scientific Officer of Enhance Skin Product Inc. ("Enhance") and Dr. Gary Hack. In March 2015 Enhance and Dr Hack filed an international application under the Patent Cooperation Treaty for the use of Hyaluronic acid and bioactive glass powder to enhance and extend the beneficial cosmetic effects of certain non-surgical dermal interventions, in particular the anti-wrinkle effects of cosmetic treatments associated with aesthetic injectables such as Botox®* (botulinum toxin) and cosmetic dermal fillers. Additional applications may include the alleviation of symptoms of rosacea such as redness, dryness and itchiness. In late 2016 National applications were filed in the USA, European Union, Australia, New Zealand and China, regions where Integumen's base patents are already granted. In December 2016 Integumen acquired all the IP and assets of Enhance.

Dr Hack is a Dental School Associate Professor in the Department of Advanced Oral Sciences and Therapeutics at the University of Maryland, School of Dentistry and the Director of Clinical Simulation. Dr. Hack has worked in the field of dentistry for the past 40 years and has worked extensively for the past 25 years with bioactive glass powders. He currently has over 30 patents and patent applications related to the usage of bioactive glasses dating back to the 1990's. He is a co-inventor of NovaMin®**, a marketed dental product which involves the use of bioactive glass for the remineralisation and desensitisation of human tooth structure. He has collaborated with Dr Asculai for a number of years on the application of bioactive glasses in the field of skincare which lead to this present invention.

Visible Youth™

Steeped in evidence-based science, Visible Youth Professional and Consumer skin care products contain the optimal size, purest and most effective HA molecular fraction and Bioactive Vitryxx®*** for deep penetrating hydration. The unique line of proprietary formulations helps restore the skin's natural supply of HA-water complex, resulting in long-lasting benefits for all skin types.

The Company's first six Visible Youth consumer products have recently completed formulation, stability and compatibility testing. The first six products include; Multi-Peptide Super Serum, Multi Action Eye Serum, Moisture Shield SPF 20, Intensive Night Recovery, Skin Clarifying Essence and Replenishing Cleaning Melt. Three of the products have also undergone tests with a panel of 65 consumers with pleasing/ exciting results.

Visible Youth Professional products focus on the treatment of skin after non-surgical procedures, an area the Company believes has been neglected by the market and for which it sees great potential. Central to the premium Visible Youth Professional brand are the proprietary patented, Healing Complex Plus 3% Lidocaine and Healing Complex intended for use after skin rejuvenation procedures such as dermabrasion or chemical peel.

Botox and Dermal Filler Market

The global market for facial aesthetics is forecast to reach $4.7 billion in 2018, of which the US is expected to contribute over US$2 billion. The global botox market is forecast to reach $2.9 billion by 2018 at a CAGR of 14%. (source: https://www.globalmarketanalyst.com/PRDetails/89/Facial-Aesthetics-Botulinum-Toxin-Dermal-Fillers-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2018)

Declan Service, CEO of Integumen, said:

"This licence completes our rights to the Botox Booster IP and represents an exciting new addition to our patent portfolio and the Visible Youth Professional product line. Initial test evaluations have provided encouraging results and we will be looking to take this technology to proof of concept stage in the near future. We look forward to collaborating with Dr. Hack on this innovative opportunity. We plan to seek development and marketing partners to take this product beyond the proof of concept stage and to launch the Visible Youth Professional line in this substantial and growing market". He went on to add; "We have also recently completed formulation and stability work for the first six Visible Youth consumer products and look forward to their launch in the European Union, the US and internationally."

* Botox® is a registered trademark of Actavis (formerly Allergan Inc).

** Novamin® is a registered trademark of GlaxoSmithKline

*** Vitryxx is a registered trademark of Schott AG

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.